1. SAT0212 Sustained Response to Mavrilimumab in Rheumatoid Arthritis Patients VIA Suppression of Macrophage and T Cells. (9th June 2015) Authors: Guo, X.; Sinibaldi, D.; Kuziora, M.; Brohawn, P.; Ryan, P.C.; Bay-Jensen, A.C.; Karsdal, M.A.; Roskos, L.K.; White, W.I. Journal: Annals of the rheumatic diseases Issue: Volume 74(2015)Supplement 2 Page Start: 734 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. SAT0260 Biomarkers Associated with Rheumatoid Arthritis Disease Activity Including Joint Damage Correlate with Changes in Clinical Response in Subjects Treated with Mavrilimumab at Doses above 10 Mg. (10th June 2014) Authors: White, W.; Ryan, P.C.; Guo, X.; Sinibaldi, D.; Ranganna, G.; Godwood, A.; Saurigny, D.; Close, D.; Eck, S.; Wilkins, D.; Roskos, L.; Sleeman, M.; Li, W.; Cavet, G.; Defranoux, N. Journal: Annals of the rheumatic diseases Issue: Volume 73:Supplement 2(2014) Page Start: 687 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗